Patents by Inventor Megan SHEEHAN

Megan SHEEHAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Splicing modulator antibody-drug conjugates and methods of use
    Patent number: 11945807
    Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: April 2, 2024
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
  • CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20230301990
    Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
    Type: Application
    Filed: March 7, 2023
    Publication date: September 28, 2023
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Andrew COOK, Dominic REYNOLDS, Cheng ZHONG, Ryan BRAWN, Shelby ELLERY, Thiwanka SAMARAKOON, Xiang LIU, Sudeep PRAJAPATI, Megan SHEEHAN, Jason T. LOWE, James PALACINO
  • Certain aryl pladienolide compounds and methods of use
    Patent number: 11679107
    Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: June 20, 2023
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Andrew Cook, Dominic Reynolds, Cheng Zhong, Ryan Brawn, Shelby Ellery, Thiwanka Samarakoon, Xiang Liu, Sudeep Prajapati, Megan Sheehan, Jason T. Lowe, James Palacino
  • PPARg MODULATORS AND METHODS OF USE
    Publication number: 20230062861
    Abstract: Disclosed herein are novel compounds of Formula (1) and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same, and methods of using the same.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 2, 2023
    Inventors: Sudeep PRAJAPATI, Hyelee LEE, Stephanos IOANNIDIS, Kiyoyuki OMOTO, Alan ROLFE, Xiang LIU, Megan SHEEHAN, Paul DRANSFIELD, Andrew COOK
  • SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20220380352
    Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
    Type: Application
    Filed: May 3, 2022
    Publication date: December 1, 2022
    Inventors: Ermira PAZOLLI, Silvia BUONAMICI, Thiwanka SAMARAKOON, Sudeep PRAJAPATI, Nathan FISHKIN, James PALACINO, Michael SEILER, Ping ZHU, Andrew COOK, Peter SMITH, Xiang LIU, Shelby ELLERY, Dominic REYNOLDS, Lihua YU, Zhenhua WU, Shouyong PENG, Nicholas CALANDRA, Megan SHEEHAN, Yonghong XIAO
  • Splicing modulator antibody-drug conjugates and methods of use
    Patent number: 11352348
    Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: June 7, 2022
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
  • SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20210299269
    Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
    Type: Application
    Filed: May 31, 2019
    Publication date: September 30, 2021
    Inventors: Ermira PAZOLLI, Silvia BUONAMICI, Thiwanka SAMARAKOON, Sudeep PRAJAPATI, Nathan FISHKIN, James PALACINO, Michael SEILER, Ping ZHU, Andrew COOK, Peter SMITH, Xiang LIU, Shelby ELLERY, Dominic REYNOLDS, Lihua YU, Zhenhua WU, Shouyong PENG, Nicholas CALANDRA, Megan SHEEHAN, Yonghong Xiao
  • CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20210177837
    Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy.
    Type: Application
    Filed: April 11, 2019
    Publication date: June 17, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Andrew COOK, Dominic REYNOLDS, Cheng ZHONG, Ryan BRAWN, Shelby ELLERY, Thiwanka SAMARAKOON, Xiang LIU, Sudeep PRAJAPATI, Megan SHEEHAN, Jason T. LOWE, James PALACINO
  • SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20210101888
    Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
    Type: Application
    Filed: November 30, 2020
    Publication date: April 8, 2021
    Inventors: Ermira PAZOLLI, Silvia BUONAMICI, Thiwanka SAMARAKOON, Sudeep PRAJAPATI, Nathan FISHKIN, James PALACINO, Michael SEILER, Ping ZHU, Andrew COOK, Peter SMITH, Xiang LIU, Shelby ELLERY, Dominic REYNOLDS, Lihua YU, Zhenhua WU, Shouyong PENG, Nicholas CALANDRA, Megan SHEEHAN, Yonghong XIAO